CIS-DICHLORODIAMMINEPLATINUM(II) ALONE AND COMBINED WITH DTIC FOR TREATMENT OF DISSEMINATED MALIGNANT-MELANOMA

Abstract

Patients with disseminated malignant melanoma were treated with cis-dichlorodiammineplatinum (II) (cis-DDP) as follows 10 with cis-DDP alone at a dose of 20 mg/m2 i.v. .times. 4 days every 4 wk and 11 with cis-DDP at a dose of 15 mg/m2 i.v. .times. 4 days combined with DTIC [5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide] at a dose of 200 mg/m2 i.v. .times. 5 days every 4 wk. Two of 21 patients (10%) showed a partial response to therapy. There were no complete responses and no apparent increases in length of survival for responders compared to nonresponders. One drug-related death occurred. Otherwise, drug toxicity was acceptable and appeared to be diminished by i.v. hydration and prolonged administration. The cis-DDP was not effective for treatment of disseminated malignant melanoma.